Table 2.
Annual change in the incident use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for patients with established cardiovascular disease and patients with no established cardiovascular disease.
| Data source | Glucagon-like peptide-1 receptor agonists | Sodium-glucose cotransporter 2 inhibitors | ||||
| Slope for patients with CVD, % (95% CI) | Slope for patients with no CVD, % (95% CI) | P value for slope difference | Slope for patients with CVD, % (95% CI) | Slope for patients with no CVD, % (95% CI) | P value for slope difference | |
| US national databases | ||||||
| CCAE | 1.87 (1.11 to 2.64) | 6.81 (3.69 to 9.92) | 0.003 | 1.43 (0.58 to 2.28) | 3.48 (1.12 to 5.85) | 0.053 |
| MDCD | 0.58 (0.36 to 0.81) | 0.92 (0.73 to 1.1) | 0.01 | 0.99 (0.71 to 1.26) | 0.83 (0.24 to 1.42) | 0.457 |
| MDCR | 5.05 (0.9 to 9.21) | 5.1 (–0.03 to 10.22) | 0.986 | 9.18 (1.1 to 17.25) | 5.62 (0.81 to 10.44) | 0.325 |
| OCEDM | 3.21 (1.72 to 4.7) | 5.51 (3.32 to 7.71) | 0.042 | 4.75 (2.27 to 7.24) | 3.94 (2.19 to 5.68) | 0.477 |
| OEHR | 2.36 (1.03 to 3.7) | 7.82 (3.77 to 11.88) | 0.007 | 3.6 (1.64 to 5.56) | 6.46 (3.42 to 9.5) | 0.06 |
| USOC | 2 (0.61 to 3.4) | 5.32 (1.74 to 8.9) | 0.044 | 2.87 (1.00 to 4.74) | 4.22 (1.28 to 7.17) | 0.313 |
| US health system databases | ||||||
| CUIMC | 1.68 (1.08 to 2.27) | 3.13 (1.59 to 4.66) | 0.04 | 3.71 (2.23 to 5.2) | 2.37 (1.34 to 3.41) | 0.074 |
| JHM | 0.75 (–0.08 to 1.58) | 2.59 (0.58 to 4.61) | 0.036 | 1.36 (0.95 to 1.77) | 2.09 (1.38 to 2.8) | 0.03 |
| STARR | 0.65 (0.17 to 1.14) | 2.07 (0.38 to 3.76) | 0.056 | 0.91 (0.56 to 1.27) | 2.01 (0.74 to 3.28) | 0.049 |
| VA | 1.4 (0.4 to 2.39) | 1.84 (0.3 to 3.39) | 0.517 | 15.94 (3.9 to 27.99) | 13.85 (2.48 to 25.22) | 0.734 |
| Non-US databases | ||||||
| ALPD | 0 | –0.1 (–0.77 to 0.56) | 0.633 | 0.63 (0.39 to 0.88) | 9.6 (4.99 to 14.2) | 0.001 |
| FLPD | 0.34 (0.07 to 0.62) | 1.35 (0.38 to 2.32) | 0.024 | 0.12 (–0.07 to 0.3) | 0.5 (–0.11 to 1.1) | 0.132 |
| GDA | 0.47 (0.11 to 0.83) | 0.92 (0.21 to 1.62) | 0.155 | 5.11 (1.75 to 8.48) | 5.22 (1.47 to 8.97) | 0.955 |
| HIC | 0 | 0.25 (–0.15 to 0.64) | 0.122 | 0.81 (–0.16 to 1.78) | 3.75 (2.49 to 5) | 0.001 |
| HKHA | NA | NA | NA | 4.98 (–3.07 to 13.04) | 4.13 (–8.35 to 16.61) | 0.542 |
| IMRD | –0.08 (–0.26 to 0.11) | 0.16 (–0.13 to 0.44) | 0.042 | 1.15 (0.11 to 2.2) | 7.24 (2.28 to 12.19) | 0.007 |
| SIDIAP | 0.27 (–0.09 to 0.62) | 0.99 (0.13 to 1.86) | 0.062 | 3.26 (1.63 to 4.89) | 6.47 (1.71 to 11.23) | 0.115 |
ALPD=Australia Longitudinal Patient Database Practice Profile; CCAE=IBM MarketScan Commercial Claims and Encounters Data; CUIMC=Columbia University Irving Medical Centre; FLPD=France Longitudinal Patient Database; GDA=Germany Disease Analyser; HIC=Health Informatics Centre at the University of Dundee, HKHA=Hong Kong Hospital Authority; IMRD=UK-IQVIA Medical Research Data, JHM=Johns Hopkins Medicine; MDCD=IBM Health MarketScan Multi-State Medicaid Database, MDCR=IBM Health MarketScan Medicare Supplemental and Coordination of Benefits Database; NA=not available; OCEDM=Optum Clinformatics Extended Data Mart-Date of Death; OEHR=Optum de-identified Electronic Health Record Dataset; SIDIAP=Information System for Research in Primary Care; STARR=Stanford Medicine; USOC=United States Open Claims, VA=Department of Veterans Affairs Healthcare System